Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nasim Nehzat

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 16, 2021
Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stageVahid Shaygannejad, Omid Mirmosayyeb, Nasim Nehzat, et al.
Autoimmunity Reviews|December 19, 2020
Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysisOmid Mirmosayyeb, Vahid Shaygannejad, Mahdi Barzegar, et al.
International Journal of Preventive Medicine|June 4, 2021
Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-AnalysisOmid Mirmosayyeb, Vahid Shaygannejad, Nasim Nehzat, et al.
Current Journal of Neurology|November 27, 2023
Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?Omid Mirmosayyeb, Mahdi Barzegar, Nasim Nehzat, et al.
Neurology Research International|August 2, 2021
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple SclerosisNasim Nehzat, Omid Mirmosayyeb, Mahdi Barzegar, et al.
Multiple Sclerosis and Related Disorders|December 15, 2020
Frequency of comorbidities in Neuromyelitis Optica spectrum disorderMahdi Barzegar, Omid Mirmosayyeb, Nasim Nehzat, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 19, 2020
The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysisOmid Mirmosayyeb, Mahdi Barzegar, Nasim Nehzat, et al.
Multiple Sclerosis and Related Disorders|May 12, 2021
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective studyMahdi Barzegar, Saeed Vaheb, Omid Mirmosayyeb, et al.
Multiple Sclerosis and Related Disorders|July 3, 2021
Early predictors of conversion to secondary progressive multiple sclerosisMahdi Barzegar, Soroush Najdaghi, Alireza Afshari-Safavi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 7, 2020
COVID-19 infection in a patient with multiple sclerosis treated with fingolimodMahdi Barzegar, Omid Mirmosayyeb, Nasim Nehzat, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 16, 2021
Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stageVahid Shaygannejad, Omid Mirmosayyeb, Nasim Nehzat, et al.
Autoimmunity Reviews|December 19, 2020
Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysisOmid Mirmosayyeb, Vahid Shaygannejad, Mahdi Barzegar, et al.
International Journal of Preventive Medicine|June 4, 2021
Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-AnalysisOmid Mirmosayyeb, Vahid Shaygannejad, Nasim Nehzat, et al.
Current Journal of Neurology|November 27, 2023
Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?Omid Mirmosayyeb, Mahdi Barzegar, Nasim Nehzat, et al.
Neurology Research International|August 2, 2021
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple SclerosisNasim Nehzat, Omid Mirmosayyeb, Mahdi Barzegar, et al.
Multiple Sclerosis and Related Disorders|December 15, 2020
Frequency of comorbidities in Neuromyelitis Optica spectrum disorderMahdi Barzegar, Omid Mirmosayyeb, Nasim Nehzat, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 19, 2020
The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysisOmid Mirmosayyeb, Mahdi Barzegar, Nasim Nehzat, et al.
Multiple Sclerosis and Related Disorders|May 12, 2021
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective studyMahdi Barzegar, Saeed Vaheb, Omid Mirmosayyeb, et al.
Multiple Sclerosis and Related Disorders|July 3, 2021
Early predictors of conversion to secondary progressive multiple sclerosisMahdi Barzegar, Soroush Najdaghi, Alireza Afshari-Safavi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 7, 2020
COVID-19 infection in a patient with multiple sclerosis treated with fingolimodMahdi Barzegar, Omid Mirmosayyeb, Nasim Nehzat, et al.
Pageof 3